CytomX Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $25,115 | $41,463 | $26,607 | $26,384 |
Gross Profit | 24,656 | 40,996 | 26,121 | 24,958 |
EBITDA | -7,993 | 12,124 | -120 | 3,123 |
EBIT | -8,452 | 11,657 | -606 | 1,697 |
Net Income | -6,534 | 13,791 | 837 | 2,992 |
Net Change In Cash | 25,115 | 41,463 | 26,607 | 26,384 |
Free Cash Flow | -19,645 | -26,160 | -22,229 | -18,252 |
Cash | 43,247 | 36,185 | 17,171 | 26,024 |
Basic Shares | 84,880 | 82,630 | 67,310 | 80,991 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $101,214 | $53,163 | $69,573 | $100,362 |
Gross Profit | 99,039 | 53,163 | 69,573 | 100,362 |
EBITDA | -4,309 | -98,892 | -81,075 | -46,032 |
EBIT | -6,484 | -101,335 | -83,781 | -51,492 |
Net Income | -569 | -97,299 | -80,648 | -32,885 |
Net Change In Cash | 101,214 | 53,163 | 69,573 | 100,362 |
Cost of Revenue | 13,671 | 13,671 | 3,434 | |
Free Cash Flow | -56,875 | -112,528 | -120,640 | 2,950 |
Cash | 17,171 | 193,650 | 205,530 | 191,859 |
Basic Shares | 73,808 | 65,739 | 64,146 | 46,145 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.08 |
2024-03-31 | $0.17 |
2023-12-31 | $0.01 |
2023-09-30 | $0.04 |
